Table 1. The 12 studies included in the meta-analysis.
| Study | Condition | Participants |
|---|---|---|
| Chang et al.,58 2019 | AD | APOE ε4 carriers=38, noncarriers=59 |
| Forno et al.,59 2023 | AD | APOE ε4 carriers=51, noncarriers=36 |
| Brys et al.,57 2009 | MCI | APOE ε4 carriers=13, noncarriers=11 |
| Novellino et al.,66 2019 | MCI | APOE ε4 carriers=40, noncarriers=55 |
| You et al.,67 2021 | MCI | APOE ε4 carriers=22, noncarriers=38 |
| Alexander et al.,56 2012 | HC | APOE ε4 carriers=14, noncarriers=10 |
| Goltermann et al.,60 2019 | HC | APOE ε4 carriers=22, noncarriers=38 |
| Honea et al.,62 2009 | HC | APOE ε4 carriers=14, noncarriers=39 |
| Honea et al.,63 2009 | HC | APOE ε4 carriers=34, noncarriers=29 |
| Honea et al.,61 2010 | HC | APOE ε4 carriers=14, noncarriers=39 |
| Nao et al.,65 2017 | HC | APOE ε4 carriers=22, noncarriers=38 |
| Mosconi et al.,64 2014 | HC | APOE ε4 carriers=19, noncarriers=33 |
AD, Alzheimer’s disease; APOE, apolipoprotein E; HC, healthy control; MCI, mild cognitive impairment.